Literature DB >> 11455784

Metabolic transit of Amadori products.

H F Erbersdobler1, V Faist.   

Abstract

In several studies, the absorption and urinary excretion of free and protein bound Amadori products were measured in rats and humans. Both, in vitro tests with everted intestinal sac preparations and in vivo experiments, showed that there is no active intestinal transport of these compounds but an absorption by diffusion. Trials with tissue slices have shown that there was an uptake into the cells of the liver, kidneys and muscles. Metabolism of Amadori products, if it exists in animals, tends to be very low. Micoorganisms in the large intestines decompose the Amadori products almost completely. The profile of urinary excretion of Amadori products after the ingestion of test meals showed a rapid elimination of the absorbed part, while the fecal output, although low because of the hind gut fermentation, persisted up to 3 days. Only 1-3% of the ingested amounts of protein bound Amadori products were recovered in the urine, which suggests a low absorption rate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455784     DOI: 10.1002/1521-3803(20010601)45:3<177::AID-FOOD177>3.0.CO;2-A

Source DB:  PubMed          Journal:  Nahrung        ISSN: 0027-769X


  15 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

2.  Do bread-crust-derived Maillard reaction products affect the retention and tissue distribution of trace elements?

Authors:  Cristina Delgado-Andrade; Irene Roncero-Ramos; Ana Haro; Silvia Pastoriza; María Pilar Navarro
Journal:  Eur J Nutr       Date:  2015-05-26       Impact factor: 5.614

Review 3.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

4.  Mass spectrometric characterization of glycated beta-lactoglobulin peptides derived from galacto-oligosaccharides surviving the in vitro gastrointestinal digestion.

Authors:  F Javier Moreno; Jesús Eduardo Quintanilla-López; Rosa Lebrón-Aguilar; Agustín Olano; María Luz Sanz
Journal:  J Am Soc Mass Spectrom       Date:  2008-04-10       Impact factor: 3.109

5.  Bioremediation of a Common Product of Food Processing by a Human Gut Bacterium.

Authors:  Ashley R Wolf; Darryl A Wesener; Jiye Cheng; Alexandra N Houston-Ludlam; Zachary W Beller; Matthew C Hibberd; Richard J Giannone; Samantha L Peters; Robert L Hettich; Semen A Leyn; Dmitry A Rodionov; Andrei L Osterman; Jeffrey I Gordon
Journal:  Cell Host Microbe       Date:  2019-10-01       Impact factor: 21.023

6.  Genome-scale metabolic reconstructions of multiple Escherichia coli strains highlight strain-specific adaptations to nutritional environments.

Authors:  Jonathan M Monk; Pep Charusanti; Ramy K Aziz; Joshua A Lerman; Ned Premyodhin; Jeffrey D Orth; Adam M Feist; Bernhard Ø Palsson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

7.  Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins.

Authors:  Alin Stirban; Paraskevi Kotsi; Knut Franke; Ulf Strijowski; Weijing Cai; Christian Götting; Diethelm Tschoepe
Journal:  Diabetes Care       Date:  2012-12-13       Impact factor: 19.112

Review 8.  Vascular Effects of Dietary Advanced Glycation End Products.

Authors:  Alin Stirban; Diethelm Tschöpe
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

Review 9.  Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management.

Authors:  Sotiria Palimeri; Eleni Palioura; Evanthia Diamanti-Kandarakis
Journal:  Diabetes Metab Syndr Obes       Date:  2015-09-01       Impact factor: 3.168

10.  Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa.

Authors:  Xin Fang; Jonathan M Monk; Nathan Mih; Bin Du; Anand V Sastry; Erol Kavvas; Yara Seif; Larry Smarr; Bernhard O Palsson
Journal:  BMC Syst Biol       Date:  2018-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.